ScreenerHero

ALLRAllarity Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · allarity.com
1.420USD-0.70%Mkt Cap: 22.59M $P/E: —

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap22.59M $
Enterprise Value23.48M $
Revenue (TTM)345.00K $
Gross Profit345.00K $
Net Income (TTM)-11.23M $
Revenue/Share0.0220 USD
Last Price1.420 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.47
PEG—
EV/EBITDA—
EV/Revenue68.06
P/S65.95
P/B2.77
EPS (TTM)-0.81
EPS (Forward)-0.97
52W Range
0.769041% of range2.350
52W High2.350 USD
52W Low0.7690 USD
Profitability
Gross Margin100.00%
Oper. Margin-10752.00%
EBITDA Margin0.00%
Profit Margin-3509.69%
ROE-114.28%
ROA-61.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.82M $
CapEx (TTM)8.00K $
FCF Margin-6076.45%
FCF Yield-92.79%
Net Debt1.68M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.14
Current Ratio1.23
Quick Ratio0.75
Book Value/Sh0.5160 USD
Cash/Share1.245 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateSep 11, 2024
Analyst Consensus
Rating—
Target (Mean)10.25 USD
Upside (mean)+621.8%
Target Range10.25 USD – 10.25 USD
# Analysts1
Ownership
Shares Out.15.91M
Float15.61M
Insiders4.19%
Institutions8.05%
Short Interest
Short Ratio1.2d
Short % Float0.76%
Short % Out.0.76%
Shares Short120.88K
Short (prev mo.)80.82K
Technical
SMA 501.298 (+9.4%)
SMA 2001.229 (+15.5%)
Beta0.51
S&P 52W Chg18.16%
Avg Vol (30d)74.85K
Avg Vol (10d)83.11K
Technical Indicators
RSI (14)59.1
MACD0.0358
MACD Signal0.0229
MACD Hist.+0.0129
BB Upper1.501 USD
BB Middle1.314 USD
BB Lower1.127 USD
BB Width28.53%
ATR (14)0.0975 USD
Vol Ratio (20d)1.54x